Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β

Masaaki Tsukigi, Vladimir Bilim, Kaori Yuuki, Andrey Ugolkov, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Teiichi Motoyama, Yoshihiko Tomita*

*Corresponding author for this work

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Recently, we have identified GSK-3 as a new therapeutic target in renal cell cancer (RCC). miR-199a could potentially downregulate GSK-3β expression. Here, we found a decreased miR-199a expression in 59% (32 of 54) of RCCs and it was correlated with higher tumor stage (p<0.05) and nuclear overexpression of GSK-3β (p<0.05). We show that re-expression of miR-199a downregulates GSK-3β and suppresses cancer cell growth. Our results demonstrate low miR-199a expression as a feature of advanced RCCs, identify miR-199a as a negative regulator of GSK-3β, and suggest re-expression of pre-miR-199a as a new potential treatment of RCC.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalCancer Letters
Volume315
Issue number2
DOIs
StatePublished - Feb 28 2012

Keywords

  • Apoptosis
  • Glycogen synthase kinase-3β
  • MiR-199
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β'. Together they form a unique fingerprint.

  • Cite this

    Tsukigi, M., Bilim, V., Yuuki, K., Ugolkov, A., Naito, S., Nagaoka, A., Kato, T., Motoyama, T., & Tomita, Y. (2012). Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β. Cancer Letters, 315(2), 189-197. https://doi.org/10.1016/j.canlet.2011.10.008